Summary
Culper Research has published a detailed report scrutinizing Axsome Therapeutics Inc. (NASDAQ: AXSM), highlighting concerns over its flagship drug Auvelity's launch strategies, revenue recognition, and associated pharmacy practices.
Who is Axsome Therapeutics
Axsome Therapeutics, founded in 2012 by CEO Herriot Tabuteau, is a biopharmaceutical company focused on developing therapies for central nervous system disorders. Its leading product, Auvelity, is a combination of two generic drugs—dextromethorphan and bupropion—targeted at major depressive disorder (MDD), but priced at roughly 30 times the cost of its generic components.
Key Points from Report
Questionable Pharmacy and Sales Practices
- Report alleges Axsome’s Auvelity launch was aided by undisclosed consignment deals with mail-order pharmacies, allowing bypass of prior authorizations (PA), which inflates script counts and revenues.
- Pharmacies like Columbia Pharmacy (South Carolina) and My Scripts Pharmacy (North Carolina) dispense Auvelity often before PA approval, frequently accepting only a $10 payment from patients instead of the full price.
- These pharmacies are affiliated with Nirav M. Patel, tied to past allegations of pharmacy fraud and kickback schemes, raising concerns about systemic fraud practices.
Financial and Audit Concerns
- Axsome reported $188.6 million in Auvelity revenues since launch, but receivables ballooned to $101.4 million, representing 148 days sales outstanding—much longer than the Company’s stated 60-day collection period.
- Revenue recognition is under scrutiny, prompted in part by the dismissal of longtime auditor Ernst & Young in June 2023 and disclosed critical audit matters in recent annual reports.
- Insider stock sales began in late 2023 for the first time since Axsome’s IPO, coinciding with cash burn of $193 million over the last twelve months.
Pricing, Coverage, and Market Challenges
- Auvelity is priced exceedingly high—over $1,000 per month—compared to its generic components costing about $32 per month, leading to stringent prior authorization and coverage restrictions by payors.
- Despite coverage claims, many commercial insurers require patients to fail multiple other drugs before approval, limiting broad adoption.
- The high price and availability of inexpensive alternatives have led some patients and physicians to pursue “DIY” options or compounding pharmacy alternatives.
Activ8 Finance Analysis
The Culper Research report raises significant concerns regarding Axsome Therapeutics' revenue recognition, operational transparency, and potential legal risks tied to pharmacy consignment practices and prior authorization circumventing. The discrepancies between reported revenues and actual cash collections, coupled with affiliate pharmacies' questionable practices, suggest risk exposure that investors and market participants may find noteworthy. While these findings do not constitute direct investment advice, the issues highlighted underscore the importance of rigorous due diligence and careful scrutiny of biopharmaceutical companies reliant on aggressive pricing and distribution tactics.